ACADIA Pharmaceuticals Inc. Net Income Common

Net Income Common of ACAD for past 10 years: annual, quarterly and twelve month trailing (TTM) including Net Income Common growth rates and interactive chart. Net income to common (NIC), also called net profit to shareholders, is calculated as sales minus cost of goods sold, selling, general and administrative expenses, operating expenses, depreciation, interest, taxes, and other expenses incuding preferred dividends. It is a useful number for investors to assess how much revenue exceeds the expenses of an organization.


Highlights and Quick Summary

  • Net Income Common for the quarter ending March 30, 2021 was $-66.4 Million (a -0.47% decrease compared to previous quarter)
  • Year-over-year quarterly Net Income Common increased by 57.68%
  • Annual Net Income Common for 2020 was $-282 Million (a 19.69% increase from previous year)
  • Annual Net Income Common for 2019 was $-235 Million (a -4.05% decrease from previous year)
  • Annual Net Income Common for 2018 was $-245 Million (a -15.28% decrease from previous year)
  • Twelve month Net Income Common ending March 30, 2021 was $-260 Million (a -7.66% decrease compared to previous quarter)
  • Twelve month trailing Net Income Common increased by 15.47% year-over-year
Trailing Net Income Common for the last four month:
30 Mar '21 30 Dec '20 29 Sep '20 29 Jun '20
$-260 Million $-282 Million $-268 Million $-225 Million
Visit stockrow.com/ACAD for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Net Income Common of ACADIA Pharmaceuticals Inc.

Most recent Net Income Commonof ACAD including historical data for past 10 years.

Interactive Chart of Net Income Common of ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. Net Income Common for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $-66.45
2020 $-66.76 $-84.66 $-42.14 $-88.02 $-281.58
2019 $-53.04 $-41.98 $-54.94 $-85.3 $-235.26
2018 $-65.49 $-62.14 $-63.27 $-54.3 $-245.19
2017 $-68.87 $-65.25 $-67.44 $-87.84 $-289.4
2016 $-78.7 $-71.61 $-71.32 $-49.76 $-271.39
2015 $-45.78 $-38.91 $-39.38 $-40.38 $-164.44
2014 $-28.37 $-24.79 $-21.5 $-17.83 $-92.48
2013 $-12.05 $-10.7 $-9.08 $-6.12 $-37.95
2012 $-6.81 $-2.4 $-5.42 $-6.22 $-20.85
2011 $-5.3 $-5.08 $-6.56 $-5.83 $-22.77
2010 $29.14 $-4.23 $-4.29 $15.14

Business Profile of ACADIA Pharmaceuticals Inc.

Sector: Healthcare
Industry: Biotechnology
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.